Roundtable Discussion: The Role of Adjuvant Therapies for NSCLC Based on Disease StageNovember 14th 2022
During a Targeted Oncology case-based roundtable event, Joel Neal, MD, PhD, and Leah Backhus, MD, MPH, discussed adjuvant therapies including chemotherapy, immunotherapy, and targeted therapy for patients with non–small cell lung cancer.
FDA Approves Tremelimumab With Durvalumab and Platinum Chemotherapy for mNSCLCNovember 10th 2022
The impressive POSEIDON clinical trial results have led to the FDA approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy for the treatment of metastatic non–small cell lung cancer.
A Commentary on High PD-L1 Expression in NSCLC
Lauren Welch, MSN, NP-C, AOCNP, describes how she approaches management of patients with NSCLC and known high PD-L1 expression while she waits for pending biomarker testing results.
Biomarkers and Biomarker Testing in NSCLC
Zosia Piotrowska, MD, and Michelle Shiller, DO, AP/CP, MGP, explain the frequency of the different biomarkers in NSCLC, and steps clinicians might take to ensure timely and effective molecular testing for their patients.
Tumor-Infiltrating Lymphocytes: Rationale for Use in the Treatment of Solid Tumors and Potential Benefits and DrawbacksNovember 8th 2022
In the second interview of this series, Ben Creelan, MD, Associate Member at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.
Roundtable Discussion: Salgia Looks at Testing and Treatment for NSCLC With EGFR Exon 20 InsertionsNovember 8th 2022
During a Targeted Oncology case-based roundtable event, Ravi Salgia, MD, PhD, discussed with participants their approach to molecular testing and treatment of a patient diagnosed with non–small cell lung cancer.
Frontline Pembrolizumab Monotherapy Continues to Elicit Clinical Benefit vs Chemo in NSCLCNovember 7th 2022
Five-year data from the phase 3 KEYNOTE-042 shows that patients with non–small cell lung cancer without EGFR/ALK alterations continue to elicit durable benefit with pembrolizumab monotherapy vs chemotherapy.
Clinical Trial Data on TILs in Non-Small Cell Lung Cancer (NSCLC)October 24th 2022
In the second installment of the series, Ben Creelan, MD, reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.
EP. 10A: Impact of Trilaciclib on Chemotherapy-Induced Myelosuppression in Patients with ES-SCLCOctober 21st 2022
Dr Mark Socinski reviews the challenges faced when treating chemotherapy induced myelosuppression and discusses the impact of trilaciclib on CIM and how that will impact clinical practice.
Reviewing Evidence for Therapies in NSCLC With EGFR Exon 20 InsertionOctober 19th 2022
During a Targeted Oncology case-based roundtable discussion, Zofia Piotrowska, MD, MHS, discussed the data from clinical trials supporting mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion mutation.
Greater Understanding of the Biology of NSCLC Propels Treatment Options ForwardOctober 17th 2022
Prior to the 20th Annual Winter Lung Cancer Conference, Mark A. Socinski, MD, spoke with Targeted Therapies in Oncology about expectations for the upcoming meeting and major topics in non–small cell lung cancer.
Dowlati Compares the Advantages and Disadvantages of Atezolizumab and Durvalumab in ES-SCLCOctober 17th 2022
During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, discussed the data supporting the use of atezolizumab and durvalumab as therapy for patients with small cell lung cancer.
Roundtable Discussion: Genetic Testing and Treatment in NSCLC With EGFR 19 Exon DeletionOctober 13th 2022
During a Targeted Oncology case-based roundtable event, Rachel E. Sanborn, MD, discussed with participants the case of a patient with metastatic lung adenocarcinoma with potential targetable biomarkers.
Novel Peptide Based Vaccine Demonstrates Safe in Advanced NSCLCOctober 7th 2022
Findings from the phase 1b/2a trial evaluating a universal cancer peptide-based vaccine at a 3-dose schedule in patients with metastatic non–small cell lung cancer showed the vaccine to be safe and effective.
Roundtable Discussion: Neal Discusses Molecular Testing and Treatment for EGFR Exon 20+ Lung CancerOctober 6th 2022
During a case-based roundtable event, Joel W. Neal, MD, PhD of Stanford Cancer Institute and a group of peers discussed using molecular testing to detect an EGFR exon 20 insertion in a patient with lung cancer.
Dostarlimab Plus Chemo Improves Responses in Patients With Advanced Non-Squamous NSCLCOctober 5th 2022
Findings from the PERLA trial examining the combination of dostarlimab with pemetrexed followed by cisplatin or carboplatin will be presented at an upcoming medical conference. GSK hints that the combination improves objective response compared with pembrolizumab and chemotherapy.
FDA Fast Tracks Sapanisertib for NRF2-Mutated Squamous Lung CancerOctober 4th 2022
After results from a phase 2 trial demonstrated durability with sapanisertib, the FDA granted fast track designation to the agent for patients with unresectable or metastatic squamous non–small cell lung cancer.
Neoadjuvant Atezolizumab Demonstrates Effectiveness in Resectable NSCLCSeptember 21st 2022
Findings of the phase 2 LCMC3 trial of atezolizumab in untreated, resectable, stage IB–IIIB non–small cell lung cancer show anti-PD-L1 monotherapy to be effective in this patient population.